The approved protocol amendment positions TSE within the earlier curative lines of therapy for patients with head & neck cancer. It represents a paradigm shift in our field of medicine, bringing TSE to the forefront of curative interventions for these indications. This strategic move marks an unprecedented milestone, redefining the landscape of electroporation treatment for cancer and is poised to transform the way cancer treatment is approached by researchers and medical practitioners.
"Securing the approval in this clinical study is undeniably the most significant milestone our team has accomplished. If the results align with the experiences of physicians in
"We are thrilled by the Ethics Committee's approval of the protocol amendment for our 'Tumour Specific Electroporation' study. This is not only a testament to the scientific rigour behind our research but also a remarkable leap forward in cancer treatment. The inclusion of TSE in earlier curative lines for head and neck patients demonstrates our commitment to pioneering solutions that make a real impact on patients' lives."- says Dr
For further information please contact:
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Certified Adviser:
E-mail: certifiedadviser@redeye.se
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on
ChemoTech is a Swedish medical technology company based in
https://news.cision.com/chemotech/r/ground-breaking-milestone-in-head---neck-cancer-treatment-achieved,c3916137
https://mb.cision.com/Main/14967/3916137/2564592.pdf
https://news.cision.com/chemotech/i/shutterstock-633181373-1,c3261163
(c) 2024 Cision. All rights reserved., source